Lv71
4348 积分 2022-01-17 加入
Cancer Medicine Approvals in the US
15天前
已完结
Cancer Medicine Approvals in the US
15天前
已完结
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
1个月前
已完结
TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?
1个月前
已完结
TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?
1个月前
已关闭
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
2个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
2个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
2个月前
已完结
皖公网安备34019202002308
